Corporate Profile

CytRx Corporation (NASDAQ: CYTR), located in Los Angeles, California, is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication, and has initiated a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors. ... More >>

Stock Chart
Stock chart for: 03NA000000CYTR
Upcoming Events
There are currently no events scheduled.
Recent Releases
04/28/17CytRx Corporation Announces Pricing of $15 Million Public Offering of Common StockPrinter Friendly Version
04/27/17CytRx Corporation Announces Proposed Public Offering of Common StockPrinter Friendly Version
04/21/17CytRx to Present Aldoxorubicin Clinical Trial Data in Patients with Soft Tissue Sarcomas at the 2017 American Society of Clinical Oncology Annual Meeting (ASCO)Printer Friendly Version
04/19/17CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue SarcomasPrinter Friendly Version
Some more press releases >
Stock Quote
CYTR (Common Stock)
ExchangeNASDAQ (US Dollar)
Financial Status IndicatorD
Change (%) Stock is Down 0.18 (25.00%)
Data as of 04/28/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Featured Report
Download Documentation 2016 10-K
Contact Information
Alexander Capital, LP
(855) 288-ALEX (2539)

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.